表紙
市場調查報告書

全球基因治療市場:各媒介類型、遺傳基因類型,及各用途 - 機會分析及產業預測(2019年∼2026年)

Gene Therapy Market by Vector Type, Gene Type, and Application : Global Opportunity Analysis and Industry Forecast, 2019-2026

出版商 Allied Market Research 商品編碼 621933
出版日期 內容資訊 英文 310 Pages
商品交期: 2-3個工作天內
價格
全球基因治療市場:各媒介類型、遺傳基因類型,及各用途 - 機會分析及產業預測(2019年∼2026年) Gene Therapy Market by Vector Type, Gene Type, and Application : Global Opportunity Analysis and Industry Forecast, 2019-2026
出版日期: 2019年12月31日內容資訊: 英文 310 Pages
簡介

全球基因治療市場在2018年估算為3億9,335萬美元的規模。該市場在2019年到2026年間,預測將以34.8%的年複合成長率成長,2026年達到62億585萬美元的規模。對遺傳基因疾病治療的DNA疫苗的高需求,針對性藥物輸送,及遺傳基因疾病的高發生率,為該市場的成長要素。還有最近,新基因治療技術開發的臨床試驗數增加,與對傳統癌症治療的基因治療的優點與政府支援增加,為該市場的促進成長因素。但,基因治療的嚴格法規核准流程和基因治療藥的高成本,有可能妨礙市場成長。

本報告提供全球基因治療市場的相關調查,市場機會,成長及阻礙因素,各媒介類型、遺傳基因類型、用途、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 報告的說明
  • 主要的優點
  • 主要市場區隔
  • 調查方法
    • 二次調查
    • 一次調查
    • 分析師的工具和模式

第2章 摘要整理

  • Cxo的見解

第3章 市場概要

  • 市場定義和範圍
  • 主要調查結果
    • 主要的投資品牌
    • 成功策略
  • 主要企業的地位
  • 波特的五力分析
  • 市場動態
    • 成長要素
    • 阻礙因素
    • 市場機會

第4章 市場分析:各媒介類型

  • 概要
    • 市場規模與預測
  • 病毒載體
    • 腺病毒
    • 慢病毒
    • 反轉錄病毒
    • 腺結合病毒
    • 單純皰疹病毒
    • 痘病毒
    • 牛痘病毒
    • 其他
  • 非病毒技術
    • 裸質體載體
    • 基因槍
    • 電穿孔
    • 脂轉染
    • 其他

第5章 市場分析:各遺傳基因類型

  • 概要
    • 市場規模與預測
  • 抗原
  • 細胞激素
  • 腫瘤抑制因素
  • 自殺遺傳基因
  • 缺乏
  • 成長因素
  • 受體
  • 其他

第6章 市場分析:各用途

  • 概要
    • 市場規模與預測
  • 腫瘤性疾病
  • 罕見疾病
  • 心血管疾病
  • 神經學的障礙
  • 感染疾病
  • 其他病

第7章 市場分析:各地區

  • 概要
    • 市場規模與預測
  • 北美
  • 歐洲
  • 亞太地區
  • 南美、中東、非洲

第8章 企業簡介

  • Adaptimmune Therapeutics Plc.
  • Anchiano Therapeutics Ltd.
  • Achieve Life Sciences, Inc.
  • Adverum Biotechnologies, Inc.
  • Abeona Therapeutics Inc.
  • Applied Genetic Technologies Corporation
  • Arbutus Biopharma Corporation
  • Audentes Therapeutics Inc.
  • Avexis Inc.
  • Bluebird Bio, Inc.
  • Celgene Corporation
  • Crispr Therapeutics Ag
  • Editas Medicine, Inc.
  • Gilead Sciences, Inc.
  • Glaxosmithkline Plc
  • Intellia Therapeutics Inc.
  • Merck & Co., Inc.
  • Novartis Ag
  • Regenxbio, Inc.
  • Spark Therapeutics, Inc.
  • Sangamo Therapeutics, Inc.
  • Uniqure N. V.
  • Voyager Therapeutics, Inc.
目錄
Product Code: LI_182841

The global gene therapy market was valued at $393.35 million in 2018, and is estimated to reach $6,205.85 million by 2026, registering a CAGR of 34.8% from 2019 to 2026.

Gene therapy is a technique that involves the delivery of nucleic acid polymers into a patient's cells as a drug to treat diseases. It fixes a genetic problem at its source. The process involves modifying the protein either to change the genetic expression or to correct a mutation. The emergence of this technology meets the rise in needs for better diagnostics and targeted therapy tools. For instance, genetic engineering can be used to modify physical appearance, metabolism, physical capabilities, and mental abilities such as memory and intelligence. In addition, it is also used for infertility treatment. Gene therapy offers a ray of hope for patients, who either have no treatment options or show no benefits with drugs currently available. The ongoing success has strongly supported upcoming researches and has carved ways for enhancement of gene therapy.

Recently, a new technique has been developed, where new genes are introduced into the body to help fight against cancer cells. Gene therapies are regarded as a potential revolution in the health sciences and pharmaceutical fields. The number of clinical trials investigating gene therapies is on an increase, despite the limited number of products that have successfully reached the market. In addition, benefits of gene therapy over conventional cancer therapies and increase in government support fuel the growth of the gene therapy market.

The gene therapy market is a widely expanding field in the pharmaceutical industry with new opportunities. This has piqued the interests of venture capitalists to explore this market and its commercial potential. Major factors that drive the growth of this market include high demands for DNA vaccines to treat genetic diseases, targeted drug delivery, and high incidence of genetic disorders. However, the stringent regulatory approval process for gene therapy and the high costs of gene therapy drugs are expected to hinder the growth of the market. On the contrary, increase in the pipeline developments for gene therapy market are expected to provide lucrative opportunity during the forecast period.

The global gene therapy market is segmented based on vector type, gene type, application, and geography. Based on vector type, it is categorized into viral vector and non-viral vector. Viral vector is further segmented into retroviruses, lentiviruses, adenoviruses, adeno associated virus, herpes simplex virus, poxvirus, vaccinia virus, and others. Non-viral vector is further categorized into naked/plasmid vectors, gene gun, electroporation, lipofection, and others. Based on gene type, the market is classified into antigen, cytokine, tumor suppressor, suicide, deficiency, growth factors, receptors, and others. Based on application, the market is divided into oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious disease, and other diseases. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY MARKET BENEFITS FOR STAKEHOLDERS

This report offers a detailed quantitative analysis of the current market trends from 2018 to 2026 to identify the prevailing opportunities.

The market estimations provided in this report are based on comprehensive analysis of the key developments in the industry.

In-depth analysis based on geography facilitates in analyzing the regional market to assist in strategic business planning.

The development strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market.

KEY MARKET SEGMENTS

By Vector Type

  • Viral vector
  • Retroviruses
  • Lentiviruses
  • Adenoviruses
  • Adeno Associated Virus
  • Herpes Simplex Virus
  • Poxvirus
  • Vaccinia Virus
  • Others
  • Non-viral vector
  • Naked/Plasmid Vectors
  • Gene Gun
  • Electroporation
  • Lipofection
  • Others

By Gene Type

  • Antigen
  • Cytokine
  • Tumor Suppressor
  • Suicide
  • Deficiency
  • Growth factors
  • Receptors
  • Others

By Application

  • Oncological Disorders
  • Rare Diseases
  • Cardiovascular Diseases
  • Neurological Disorders
  • Infectious disease
  • Other Diseases

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • South Africa
  • Saudi Arabia
  • Rest of LAMEA

KEY PLAYERS PROFILED

  • Adaptimmune Therapeutics Plc.
  • Anchiano Therapeutics Ltd.
  • Achieve Life Sciences, Inc.
  • Adverum Biotechnologies, Inc.
  • Abeona Therapeutics Inc.
  • Applied Genetic Technologies Corporation
  • Arbutus Biopharma Corporation,
  • Audentes Therapeutics, Inc.
  • AveXis, Inc.
  • Bluebird Bio, Inc.
  • Celgene Corporation
  • CRISPR Therapeutics AG
  • Editas Medicine, Inc.
  • Editas Medicine, Inc.
  • GlaxoSmithKline Plc.
  • Intellia Therapeutics, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • REGENXBIO Inc.
  • Spark Therapeutics, Inc.
  • Sangamo Therapeutics, Inc.
  • Uniqure N. V.
  • Voyager Therapeutics, Inc 

The other players of the gene therapy market include (companies not profiled in the report):

  • Amgen
  • Epeius Biotechnologies
  • Sanofi
  • Juno Therapeutics
  • Advantagene

Table of Contents

Chapter 1: Introduction

  • 1.1. Report Description
  • 1.2. Key Benefits
  • 1.3. Key Market Segments
  • 1.4. Research Methodology
    • 1.4.1. Secondary Research
    • 1.4.2. Primary Research
    • 1.4.3. Analyst Tools And Models

Chapter 2: Executive Summary

  • 2.1. Cxo Perspective

Chapter 3: Market Overview

  • 3.1. Market Definition And Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Top Player Positioning, 2018
  • 3.4. Porter'S Five Forces Analysis
  • 3.5. Market Dynamics
    • 3.5.1. Drivers
      • 3.5.1.1. High Investment For R&D Activities Pertaining To Gene Therapy
      • 3.5.1.2. Increase In Prevalence of Cancer
      • 3.5.1.3. Growth In Awareness Regarding Gene Therapy
    • 3.5.2. Restraints
      • 3.5.2.1. High Cost Associated With Gene Therapies
      • 3.5.2.2. Unwanted Immune Responses
    • 3.5.3. Opportunities
      • 3.5.3.1. Untapped Potential For Emerging Markets

Chapter 4: Gene Therapy Market, By Vector Type

  • 4.1. Overview
    • 4.1.1. Market Size And Forecast
  • 4.2. Viral Vectors
    • 4.2.1. Key Market Trends, Growth Factors, And Opportunities
    • 4.2.2. Market Size And Forecast, By Region
    • 4.2.3. Market Size And Forecast, By Type
    • 4.2.4. Market Size And Forecast, By Country
    • 4.2.5. Adenovirus
    • 4.2.6. Lentivirus
    • 4.2.7. Retrovirus
    • 4.2.8. Adeno-Associated Virus
    • 4.2.9. Herpes Simplex Virus
    • 4.2.10. Poxvirus
    • 4.2.11. Vaccinia Virus
    • 4.2.12. Others
  • 4.3. Non-Viral Techniques
    • 4.3.1. Key Market Trends, Growth Factors, And Opportunities
    • 4.3.2. Market Size And Forecast, By Region
    • 4.3.3. Market Size And Forecast, By Type
    • 4.3.4. Market Size And Forecast, By Country
    • 4.3.5. Naked Plasmid Vector
    • 4.3.6. Gene Gun
    • 4.3.7. Electroporation
    • 4.3.8. Lipofection
    • 4.3.9. Others

Chapter 5: Gene Therapy Market, By Gene Type

  • 5.1. Overview
    • 5.1.1. Market Size And Forecast, Type
  • 5.2. Antigen
    • 5.2.1. Market Size And Forecast
    • 5.2.2. Market Size And Forecast, By Country
  • 5.3. Cytokine
    • 5.3.1. Market Size And Forecast
    • 5.3.2. Market Size And Forecast, By Country
  • 5.4. Tumor Suppressor
    • 5.4.1. Market Size And Forecast, By Region
    • 5.4.2. Market Size And Forecast, By Country
  • 5.5. Suicide Gene
    • 5.5.1. Market Size And Forecast
    • 5.5.2. Market Size And Forecast, By Country
  • 5.6. Deficiency
    • 5.6.1. Market Size And Forecast, By Region
    • 5.6.2. Market Size And Forecast, By Country
  • 5.7. Growth Factors
    • 5.7.1. Market Size And Forecast, By Region
    • 5.7.2. Market Size And Forecast, By Country
  • 5.8. Receptors
    • 5.8.1. Market Size And Forecast, By Region
    • 5.8.2. Market Size And Forecast, By Country
  • 5.9. Others
    • 5.9.1. Market Size And Forecast, By Region
    • 5.9.2. Market Size And Forecast, By Country

Chapter 6: Gene Therapy Market, By Application

  • 6.1. Overview
    • 6.1.1. Market Size And Forecast, By Application
  • 6.2. Oncological Disorders
    • 6.2.1. Market Size And Forecast, By Region
    • 6.2.2. Market Size And Forecast, By Country
  • 6.3. Rare Diseases
    • 6.3.1. Market Size And Forecast, By Region
    • 6.3.2. Market Size And Forecast, By Country
  • 6.4. Cardiovascular Diseases
    • 6.4.1. Market Size And Forecast, By Region
    • 6.4.2. Market Size And Forecast, By Country
  • 6.5. Neurological Disorders
    • 6.5.1. Market Size And Forecast
    • 6.5.2. Market Size And Forecast, By Country
  • 6.6. Infectious Diseases
    • 6.6.1. Market Size And Forecast, By Region
    • 6.6.2. Market Size And Forecast, By Country
  • 6.7. Other Diseases
    • 6.7.1. Market Size And Forecast
    • 6.7.2. Market Size And Forecast, By Country

Chapter 7: Gene Therapy Market, By Region

  • 7.1. Overview
    • 7.1.1. Market Size And Forecast
  • 7.2. North America
    • 7.2.1. Key Market Trends, Growth Factors, And Opportunities
    • 7.2.2. Market Size And Forecast, By Country
    • 7.2.3. Market Size And Forecast, By Vector Type
    • 7.2.4. Market Size And Forecast, By Gene Type
    • 7.2.5. Market Size And Forecast, By Application
      • 7.2.5.1. U.S. Market Size And Forecast, By Vector Type
      • 7.2.5.2. U.S. Market Size And Forecast, By Gene Type
      • 7.2.5.3. U.S. Market Size And Forecast, By Application
      • 7.2.5.4. Canada Market Size And Forecast, By Vector Type
      • 7.2.5.5. Canada Market Size And Forecast, By Gene Type
      • 7.2.5.6. Canada Market Size And Forecast, By Application
      • 7.2.5.7. Mexico Market Size And Forecast, By Vector Type
      • 7.2.5.8. Mexico Market Size And Forecast, By Gene Type
      • 7.2.5.9. Mexico Market Size And Forecast, By Application
  • 7.3. Europe
    • 7.3.1. Key Market Trends, Growth Factors, And Opportunities
    • 7.3.2. Market Size And Forecast, By Country
    • 7.3.3. Market Size And Forecast, By Vector Type
    • 7.3.4. Market Size And Forecast, By Gene Type
    • 7.3.5. Market Size And Forecast, By Application
      • 7.3.5.1. Germany Market Size And Forecast, By Vector Type
      • 7.3.5.2. Germany Market Size And Forecast, By Gene Type
      • 7.3.5.3. Germany Market Size And Forecast, By Application
      • 7.3.5.4. France Market Size And Forecast, By Vector Type
      • 7.3.5.5. France Market Size And Forecast, By Gene Type
      • 7.3.5.6. France Market Size And Forecast, By Application
      • 7.3.5.7. Uk Market Size And Forecast, By Vector Type
      • 7.3.5.8. Uk Market Size And Forecast, By Gene Type
      • 7.3.5.9. Uk Market Size And Forecast, By Application
      • 7.3.5.10. Italy Market Size And Forecast, By Vector Type
      • 7.3.5.11. Italy Market Size And Forecast, By Gene Type
      • 7.3.5.12. Italy Market Size And Forecast, By Application
      • 7.3.5.13. Spain Market Size And Forecast, By Vector Type
      • 7.3.5.14. Spain Market Size And Forecast, By Gene Type
      • 7.3.5.15. Spain Market Size And Forecast, By Application
      • 7.3.5.16. Rest of Europe Market Size And Forecast, By Vector Type
      • 7.3.5.17. Rest of Europe Market Size And Forecast, By Gene Type
      • 7.3.5.18. Rest of Europe Market Size And Forecast, By Application
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends, Growth Factors, And Opportunities
    • 7.4.2. Market Size And Forecast, By Country
    • 7.4.3. Market Size And Forecast, By Vector Type
    • 7.4.4. Market Size And Forecast, By Gene Type
    • 7.4.5. Market Size And Forecast, By Application
      • 7.4.5.1. Japan Market Size And Forecast, By Vector Type
      • 7.4.5.2. Japan Market Size And Forecast, By Gene Type
      • 7.4.5.3. Japan Market Size And Forecast, By Application
      • 7.4.5.4. China Market Size And Forecast, By Vector Type
      • 7.4.5.5. China Market Size And Forecast, By Gene Type
      • 7.4.5.6. China Market Size And Forecast, By Application
      • 7.4.5.7. India Market Size And Forecast, By Vector Type
      • 7.4.5.8. India Market Size And Forecast, By Gene Type
      • 7.4.5.9. India Market Size And Forecast, By Application
      • 7.4.5.10. South Korea Market Size And Forecast, By Vector Type
      • 7.4.5.11. South Korea Market Size And Forecast, By Gene Type
      • 7.4.5.12. South Korea Market Size And Forecast, By Application
      • 7.4.5.13. Rest of Asia-Pacific Market Size And Forecast, By Vector Type
      • 7.4.5.14. Rest of Asia-Pacific Market Size And Forecast, By Gene Type
      • 7.4.5.15. Rest of Asia-Pacific Market Size And Forecast, By Application
  • 7.5. Lamea
    • 7.5.1. Key Market Trends, Growth Factors, And Opportunities
    • 7.5.2. Market Size And Forecast, By Country
    • 7.5.3. Market Size And Forecast, By Vector Type
    • 7.5.4. Market Size And Forecast, By Gene Type
    • 7.5.5. Market Size And Forecast, By Application
      • 7.5.5.1. Brazil Market Size And Forecast, By Vector Type
      • 7.5.5.2. Brazil Market Size And Forecast, By Gene Type
      • 7.5.5.3. Brazil Market Size And Forecast, By Application
      • 7.5.5.4. South Africa Market Size And Forecast, By Vector Type
      • 7.5.5.5. South Africa Market Size And Forecast, By Gene Type
      • 7.5.5.6. South Africa Market Size And Forecast, By Application
      • 7.5.5.7. Rest of Lamea Market Size And Forecast, By Vector Type
      • 7.5.5.8. Rest of Lamea Market Size And Forecast, By Gene Type
      • 7.5.5.9. Rest of Lamea Market Size And Forecast, By Application

Chapter 8: Company Profile

  • 8.1. Adaptimmune Therapeutics Plc.
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Operating Business Segments
    • 8.1.4. Product Portfolio
    • 8.1.5. Business Performance
    • 8.1.6. Key Strategic Moves And Developments
  • 8.2. Anchiano Therapeutics Ltd.
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Operating Business Segments
    • 8.2.4. Product Portfolio
  • 8.3. Achieve Life Sciences, Inc.
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Operating Business Segments
    • 8.3.4. Product Portfolio
    • 8.3.5. Key Strategic Moves And Developments
  • 8.4. Adverum Biotechnologies, Inc.
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Operating Business Segments
    • 8.4.4. Product Portfolio
    • 8.4.5. Key Strategic Moves And Developments
  • 8.5. Abeona Therapeutics Inc.
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Operating Business Segments
    • 8.5.4. Product Portfolio
    • 8.5.5. Business Performance
    • 8.5.6. Key Strategic Moves And Developments
  • 8.6. Applied Genetic Technologies Corporation
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Operating Business Segments
    • 8.6.4. Product Portfolio
    • 8.6.5. Business Performance
    • 8.6.6. Key Strategic Moves And Developments
  • 8.7. Arbutus Biopharma Corporation
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Product Portfolio
    • 8.7.4. Business Performance
    • 8.7.5. Key Strategic Moves And Developments
  • 8.8. Audentes Therapeutics Inc.
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Product Portfolio
    • 8.8.4. Key Strategic Moves And Developments
  • 8.9. Avexis Inc.
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Product Portfolio
    • 8.9.4. Key Strategic Moves And Developments
  • 8.10. Bluebird Bio, Inc.
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Operating Business Segments
    • 8.10.4. Product Portfolio
    • 8.10.5. Business Performance
    • 8.10.6. Key Strategic Moves And Developments
  • 8.11. Celgene Corporation
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Operating Business Segments
    • 8.11.4. Product Portfolio
    • 8.11.5. Business Performance
    • 8.11.6. Key Strategic Moves And Developments
  • 8.12. Crispr Therapeutics Ag
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Product Portfolio
    • 8.12.4. Business Performance
    • 8.12.5. Key Strategic Moves And Developments
  • 8.13. Editas Medicine, Inc.
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Operating Business Segments
    • 8.13.4. Product Portfolio
    • 8.13.5. Business Performance
    • 8.13.6. Key Strategic Moves And Developments
  • 8.14. Gilead Sciences, Inc.
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Operating Business Segments
    • 8.14.4. Product Portfolio
    • 8.14.5. Business Performance
    • 8.14.6. Key Strategic Moves And Developments
  • 8.15. Glaxosmithkline Plc
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Operating Business Segments
    • 8.15.4. Product Portfolio
    • 8.15.5. Business Performance
    • 8.15.6. Key Strategic Moves And Developments
  • 8.16. Intellia Therapeutics Inc.
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Operating Business Segments
    • 8.16.4. Product Portfolio
    • 8.16.5. Business Performance
    • 8.16.6. Key Strategic Moves And Developments
  • 8.17. Merck & Co., Inc.
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Operating Business Segments
    • 8.17.4. Product Portfolio
    • 8.17.5. Business Performance
    • 8.17.6. Key Strategic Moves And Developments
  • 8.18. Novartis Ag
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Operating Business Segments
    • 8.18.4. Product Portfolio
    • 8.18.5. Business Performance
    • 8.18.6. Key Strategic Moves And Developments
  • 8.19. Regenxbio, Inc.
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Product Portfolio
    • 8.19.4. Business Performance
    • 8.19.5. Key Strategic Moves And Developments
  • 8.20. Spark Therapeutics, Inc.
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Operating Business Segments
    • 8.20.4. Product Portfolio
    • 8.20.5. Business Performance
    • 8.20.6. Key Strategic Moves And Developments
  • 8.21. Sangamo Therapeutics, Inc.
    • 8.21.1. Company Overview
    • 8.21.2. Company Snapshot
    • 8.21.3. Operating Business Segments
    • 8.21.4. Product Portfolio
    • 8.21.5. Business Performance
    • 8.21.6. Key Strategic Moves And Developments
  • 8.22. Uniqure N. V.
    • 8.22.1. Company Overview
    • 8.22.2. Company Snapshot
    • 8.22.3. Operation Segments
    • 8.22.4. Product Portfolio
    • 8.22.5. Business Performance
    • 8.22.6. Key Strategic Moves And Developments
  • 8.23. Voyager Therapeutics, Inc.
    • 8.23.1. Company Overview
    • 8.23.2. Company Snapshot
    • 8.23.3. Operating Business Segments
    • 8.23.4. Product Portfolio
    • 8.23.5. Business Performance
    • 8.23.6. Key Strategic Moves And Developments

List of Tables

  • Table 01. Late-Stage Clinical Data Events of Gene Therpy
  • Table 02. Gene Therapy Pipeline Volume, Preclinical Through Pre-Registration Phase, 1995-2018
  • Table 03. Global Gene Therapy Market, By Vector Type, 2018-2026 ($Million)
  • Table 04. Global Gene Therapy Market For Viral Vectors, By Region, 2018-2026 ($Million)
  • Table 05. Global Gene Therapy Market For Viral Vectors, By Type, 2018-2026 ($Million)
  • Table 06. Gene Therapy Market For Non-Viral Vectors, By Region, 2018-2026 ($Million)
  • Table 07. Global Gene Therapy Market For Non-Viral Vectors, By Type, 2018-2026 ($Million)
  • Table 08. Global Gene Therapy Market, By Gene Type, 2018-2026 ($Million)
  • Table 09. Antigen Gene Therapy Market, By Region, 2018-2026 ($Million)
  • Table 10. Cytokine Gene Therapy Market, By Region, 2018-2026 ($Million)
  • Table 11. Tumor Suppressor Gene Therapy Market, By Region, 2018-2026 ($Million)
  • Table 12. Suicide Gene Therapy Market, By Region, 2018-2026 ($Million)
  • Table 13. Deficiency Gene Therapy Market, By Region, 2018-2026 ($Million)
  • Table 14. Growth Factors Gene Therapy Market, By Region, 2018-2026 ($Million)
  • Table 15. Receptors Gene Therapy Market, By Region, 2018-2026 ($Million)
  • Table 16. Gene Therapy Market For Other Gene Types, By Region, 2018-2026 ($Million)
  • Table 17. Global Gene Therapy Market, By Application, 2018-2026 ($Million)
  • Table 18. Gene Therapy Market For Oncological Disorders, By Region, 2018-2026 ($Million)
  • Table 19. Gene Therapy Market For Rare Diseases, By Region, 2018-2026 ($Million)
  • Table 20. Gene Therapy Market For Cardiovascular Diseases, By Region, 2018-2026 ($Million)
  • Table 21. Gene Therapy Market For Neurological Disorders, By Region, 2018-2026 ($Million)
  • Table 22. Gene Therapy Market For Infectious Diseases, By Region, 2018-2026 ($Million)
  • Table 23. Gene Therapy Market For Other Diseases, By Region, 2018-2026 ($Million)
  • Table 24. Gene Therapy Market, By Region, 2018-2026 ($Million)
  • Table 25. North America Gene Therapy Market, By Country, 2018-2026 ($Million)
  • Table 26. North America Gene Therapy Market, By Vector Type, 2018-2026 ($Million)
  • Table 27. North America Gene Therapy Market, By Gene Type, 2018-2026 ($Million)
  • Table 28. North America Gene Therapy Market, By Application, 2018-2026 ($Million)
  • Table 29. U.S. Gene Therapy Market, By Vector Type, 2018-2026 ($Million)
  • Table 30. U.S. Gene Therapy Market, By Gene Type, 2018-2026 ($Million)
  • Table 31. U.S. Gene Therapy Market, By Application, 2018-2026 ($Million)
  • Table 32. Canada Gene Therapy Market, By Vector Type, 2018-2026 ($Million)
  • Table 33. Canada Gene Therapy Market, By Gene Type, 2018-2026 ($Million)
  • Table 34. Canada Gene Therapy Market, By Application, 2018-2026 ($Million)
  • Table 35. Mexico Gene Therapy Market, By Vector Type, 2018-2026 ($Million)
  • Table 36. Mexico Gene Therapy Market, By Gene Type, 2018-2026 ($Million)
  • Table 37. Mexico Gene Therapy Market, By Application, 2018-2026 ($Million)
  • Table 38. Europe Gene Therapy Market, By Country, 2018-2026 ($Million)
  • Table 39. Europe Gene Therapy Market, By Vector Type, 2018-2026 ($Million)
  • Table 40. Europe Gene Therapy Market, By Gene Type, 2018-2026 ($Million)
  • Table 41. Europe Gene Therapy Market, By Application, 2018-2026 ($Million)
  • Table 42. Germany Gene Therapy Market, By Vector Type, 2018-2026 ($Million)
  • Table 43. Germany Gene Therapy Market, By Gene Type, 2018-2026 ($Million)
  • Table 44. Germany Gene Therapy Market, By Application, 2018-2026 ($Million)
  • Table 45. France Gene Therapy Market, By Vector Type, 2018-2026 ($Million)
  • Table 46. France Gene Therapy Market, By Gene Type, 2018-2026 ($Million)
  • Table 47. France Gene Therapy Market, By Application, 2018-2026 ($Million)
  • Table 48. Uk Gene Therapy Market, By Vector Type, 2018-2026 ($Million)
  • Table 49. Uk Gene Therapy Market, By Gene Type, 2018-2026 ($Million)
  • Table 50. Uk Gene Therapy Market, By Application, 2018-2026 ($Million)
  • Table 51. Italy Gene Therapy Market, By Vector Type, 2018-2026 ($Million)
  • Table 52. Italy Gene Therapy Market, By Gene Type, 2018-2026 ($Million)
  • Table 53. Italy Gene Therapy Market, By Application, 2018-2026 ($Million)
  • Table 54. Spain Gene Therapy Market, By Vector Type, 2018-2026 ($Million)
  • Table 55. Spain Gene Therapy Market, By Gene Type, 2018-2026 ($Million)
  • Table 56. Spain Gene Therapy Market, By Application, 2018-2026 ($Million)
  • Table 57. Rest of Europe Gene Therapy Market, By Vector Type, 2018-2026 ($Million)
  • Table 58. Rest of Europe Gene Therapy Market, By Gene Type, 2018-2026 ($Million)
  • Table 59. Rest of Europe Gene Therapy Market, By Application, 2018-2026 ($Million)
  • Table 60. Asia-Pacific Gene Therapy Market, By Country, 2018-2026 ($Million)
  • Table 61. Asia-Pacific Gene Therapy Market, By Vector Type, 2018-2026 ($Million)
  • Table 62. Asia-Pacific Gene Therapy Market, By Gene Type, 2018-2026 ($Million)
  • Table 63. Asia-Pacific Gene Therapy Market, By Application, 2018-2026 ($Million)
  • Table 64. Japan Gene Therapy Market, By Vector Type, 2018-2026 ($Million)
  • Table 65. Japan Gene Therapy Market, By Gene Type, 2018-2026 ($Million)
  • Table 66. Japan Gene Therapy Market, By Application, 2018-2026 ($Million)
  • Table 67. China Gene Therapy Market, By Vector Type, 2018-2026 ($Million)
  • Table 68. China Gene Therapy Market, By Gene Type, 2018-2026 ($Million)
  • Table 69. China Gene Therapy Market, By Application, 2018-2026 ($Million)
  • Table 70. India Gene Therapy Market, By Vector Type, 2018-2026 ($Million)
  • Table 71. India Gene Therapy Market, By Gene Type, 2018-2026 ($Million)
  • Table 72. India Gene Therapy Market, By Application, 2018-2026 ($Million)
  • Table 73. South Korea Gene Therapy Market, By Vector Type, 2018-2026 ($Million)
  • Table 74. South Korea Gene Therapy Market, By Gene Type, 2018-2026 ($Million)
  • Table 75. South Korea Gene Therapy Market, By Application, 2018-2026 ($Million)
  • Table 76. Rest of Asia-Pacific Gene Therapy Market, By Vector Type, 2018-2026 ($Million)
  • Table 77. Rest of Asia-Pacific Gene Therapy Market, By Gene Type, 2018-2026 ($Million)
  • Table 78. Rest of Asia-Pacific Gene Therapy Market, By Application, 2018-2026 ($Million)
  • Table 79. Lamea Gene Therapy Market, By Country, 2018-2026 ($Million)
  • Table 80. Lamea Gene Therapy Market, By Vector Type, 2018-2026 ($Million)
  • Table 81. Lamea Gene Therapy Market, By Gene Type, 2018-2026 ($Million)
  • Table 82. Lamea Gene Therapy Market, By Application, 2018-2026 ($Million)
  • Table 83. Brazil Gene Therapy Market, By Vector Type, 2018-2026 ($Million)
  • Table 84. Brazil Gene Therapy Market, By Gene Type, 2018-2026 ($Million)
  • Table 85. Brazil Gene Therapy Market, By Application, 2018-2026 ($Million)
  • Table 86. South Africa Gene Therapy Market, By Vector Type, 2018-2026 ($Million)
  • Table 87. South Africa Gene Therapy Market, By Gene Type, 2018-2026 ($Million)
  • Table 88. South Africa Gene Therapy Market, By Application, 2018-2026 ($Million)
  • Table 89. Rest of Lamea Gene Therapy Market, By Vector Type, 2018-2026 ($Million)
  • Table 90. Rest of Lamea Gene Therapy Market, By Gene Type, 2018-2026 ($Million)
  • Table 91. Rest of Lamea Gene Therapy Market, By Application, 2018-2026 ($Million)
  • Table 92. Adaptimmune: Company Snapshot
  • Table 93. Adaptimmune: Business Unit
  • Table 94. Adaptimmune.: Product Portfolio
  • Table 95. Anchiano Therapeutics: Company Snapshot
  • Table 96. Anchiano Therapeutics: Product Category
  • Table 97. Anchiano Therapeutics: Product Portfolio
  • Table 98. Achieve Life Sciences.: Company Snapshot
  • Table 99. Achieve Life Sciences.: Operating Segments
  • Table 100. Achieve Life Sciences: Product Portfolio
  • Table 101. Adverum Biotechnologies, Inc.: Company Snapshot
  • Table 102. Adverum Biotechnologies, Inc.: Product Category
  • Table 103. Adverum Biotechnologies, Inc.: Product Portfolio
  • Table 104. Abeona Therapeutics Inc.: Company Snapshot
  • Table 105. Abeona Therapeutics Inc.: Product Category
  • Table 106. Abeona Therapeutics Inc.: Product Portfolio
  • Table 107. Applied Genetic Technologies Corporation: Company Snapshot
  • Table 108. Applied Genetic Technologies Corporation: Operating Segments
  • Table 109. Applied Genetic Technologies Corporation: Product Portfolio
  • Table 110. Arbutus: Company Snapshot
  • Table 111. Arbutus: Product Portfolio
  • Table 112. Audentes: Company Snapshot
  • Table 113. Audentes: Product Portfolio
  • Table 114. Avexis: Company Snapshot
  • Table 115. Avexis: Product Portfolio
  • Table 116. Bluebird Bio : Company Snapshot
  • Table 117. Bluebird Bio: Product Category
  • Table 118. Bluebird Bio.: Product Portfolio
  • Table 119. Celgene: Company Snapshot
  • Table 120. Celgene: Operating Segments
  • Table 121. Celgene: Product Portfolio
  • Table 122. Crispr: Company Snapshot
  • Table 123. Crispr: Product Portfolio
  • Table 124. Editas.: Company Snapshot
  • Table 125. Editas: Product Portfolio
  • Table 126. Gilead: Company Snapshot
  • Table 127. Gilead: Operating Segments
  • Table 128. Gilead: Product Portfolio
  • Table 129. Gsk.: Company Snapshot
  • Table 130. Gsk: Operating Segments
  • Table 131. Gsk: Product Portfolio
  • Table 132. Intellia: Company Snapshot
  • Table 133. Intellia: Product Portfolio
  • Table 134. Merck: Company Snapshot
  • Table 135. Merck: Operating Segments
  • Table 136. Merck.: Product Portfolio
  • Table 137. Novartis: Company Snapshot
  • Table 138. Novartis: Operating Division
  • Table 139. Novartis: Product Portfolio
  • Table 140. Regenxbio: Company Snapshot
  • Table 141. Regenxbio: Product Portfolio
  • Table 142. Spark Therapeutics: Company Snapshot
  • Table 143. Spark Therapeutics, Inc.: Product Category
  • Table 144. Spark Therapeutics, Inc.: Product Portfolio
  • Table 145. Sangamo Therapeutics: Company Snapshot
  • Table 146. Sangamo Therapeutics: Operating Business Segments
  • Table 147. Sangamo Therapeutics: Product Portfolio
  • Table 148. Uniqure: Company Snapshot
  • Table 149. Uniqure: Product Business Segment
  • Table 150. Uniqure.: Product Portfolio
  • Table 151. Voyager.: Company Snapshot
  • Table 152. Voyager : Product Business Segments
  • Table 153. Voyager.: Product Portfolio

List of Figures

  • Figure 01. Global Gene Therapy Market Segmentation
  • Figure 02. Top Investment Pockets: By Gene Type, 2018
  • Figure 03. Top Winning Strategies, By Year, 2016-2019*
  • Figure 04. Top Winning Strategies, By Development, 2016-2019* (%)
  • Figure 05. Top Winning Strategies, By Company, 2016-2019*
  • Figure 06. Top Player Positioning, 2018
  • Figure 07. Low Bargaining Power of Buyers
  • Figure 08. High Bargaining Power of Suppliers
  • Figure 09. High Threat of New Entrants
  • Figure 10. Moderate Threat of Substitution
  • Figure 11. High Competitive Rivalry
  • Figure 12. Restraints And Drivers: Global Gene Therapy Market
  • Figure 13. Comparative Regional Share Analysis of Gene Therapy Market For Viral Vectors, 2018 Vs 2026 ($Million)
  • Figure 14. Comparative Analysis of Gene Therapy Market For Non-Viral Vectors, 2018 Vs 2026 (%)
  • Figure 15. Comparative Analysis of Antigen Gene Therapy Market, By Country, 2018 Vs 2026 (%)
  • Figure 16. Comparative Analysis of Cytokine Gene Therapy Market, By Country, 2018 Vs 2026 (%)
  • Figure 17. Comparative Analysis of Tumor Suppressor Gene Therapy Market, By Country, 2018 Vs 2026 (%)
  • Figure 18. Comparative Analysis of Suicide Gene Therapy Market, By Country, 2018 Vs 2026 (%)
  • Figure 19. Comparative Analysis of Deficiency Gene Therapy Market, By Country, 2018 Vs 2026 (%)
  • Figure 20. Comparative Analysis of Growth Factors Gene Therapy Market, By Country, 2018 Vs 2026(%)
  • Figure 21. Comparative Analysis of Receptors Gene Therapy Market, By Country, 2018 Vs 2026 (%)
  • Figure 22. Comparative Analysis of Gene Therapy Market For Other Gene Types, 2018 Vs 2026 (%)
  • Figure 23. Comparative Analysis of Gene Therapy Market For Oncological Disorders, 2018 Vs 2026 (%)
  • Figure 24. Comparative Analysis of Gene Therapy Market For Rare Diseases, 2018 Vs 2026 (%)
  • Figure 25. Comparative Analysis of Gene Therapy Market For Cardiovascular Diseases, 2018 Vs 2026 (%)
  • Figure 26. Comparative Analysis of Gene Therapy Market For Neurological Disorders, 2018 Vs 2026 (%)
  • Figure 27. Comparative Analysis of Gene Therapy Market For Infectious Diseases, 2018 Vs 2026 (%)
  • Figure 28. Comparative Analysis of Gene Therapy Market For Other Diseases, 2018 Vs 2026 (%)
  • Figure 29. Adaptimmune: Revenue, 2016-2018($Million)
  • Figure 30. Adaptimmune: Segmentation, 2016-2018(%)
  • Figure 31. Abeona Therapeutics Inc.: Net Sales, 2014-2016 ($Million)
  • Figure 32. Applied Genetic Technologies Corporation: Net Sales, 2015-2017 ($Million)
  • Figure 33. Arbutus: Net Sales, 2016-2018 ($Million)
  • Figure 34. Bluebird Bio: Revenue, 2016-2018($Million)
  • Figure 35. Celgene: Revenue, 2016-2018($Million)
  • Figure 36. Celgene: Revenue Share By Product, 2018 (%)
  • Figure 37. Celgene: Revenue Share By Region, 2018 (%)
  • Figure 38. Crispr: Net Sales, 2016-2018 ($Million)
  • Figure 39. Editas: Net Sales, 2016-2018 ($Million)
  • Figure 40. Gilead: Revenue, 2016-2018($Million)
  • Figure 41. Gilead: Revenue Share By Region, 2018 (%)
  • Figure 42. Gsk: Revenue, 2016-2018($Million)
  • Figure 43. Gsk: Revenue Share By Segment, 2018 (%)
  • Figure 44. Gsk: Revenue Share By Region, 2018 (%)
  • Figure 45. Intellia: Net Sales, 2016-2018 ($Million)
  • Figure 46. Merck: Revenue, 2016-2018($Million)
  • Figure 47. Merck: Revenue Share By Segment, 2018 (%)
  • Figure 48. Merck: Revenue Share By Region, 2018 (%)
  • Figure 49. Novartis: Revenue, 2016-2018 ($Million)
  • Figure 50. Novartis: Revenue Share By Segment, 2018 (%)
  • Figure 51. Novartis: Revenue Share By Region, 2018 (%)
  • Figure 52. Regenxbio: Net Sales, 2016-2018 ($Million)
  • Figure 53. Spark Therapeutics, Inc.: Revenue, 2016-2018 ($Million)
  • Figure 54. Sangamo Therapeutics: Net Sales, 2016-2018 ($Million)
  • Figure 55. Uniqure.: Net Sales, 2016-2018 ($Million)
  • Figure 56. Voyager: Net Sales, 2016-2018 ($Million)